Emergent BioSolutions tumbles 14% after J&J says it spoiled 15 million COVID-19 vaccine doses

• Shares of Emergent BioSolutions tumbled 14% after it spoiled Johnson & Johnson vaccines.
• According to The New York Times, the spoilage that affected 15 million vaccine doses was due to human error.
• The contract manufacturer produces both the J&J and AstraZeneca vaccines, which the NYT reports it mixed together.

$4 tumbled as much as 14.5% on Thursday after Johnson & Johnson said the $4.

Emergent BioSolutions is a contract manufacturer that produces both the Johnson & Johnson and AstraZeneca coronavirus vaccines.

$4, the vaccine spoilage was due to human error, when workers at the plant mixed up the ingredients of the Johnson & Johnson and AstraZeneca vaccines.

The Maryland-based company fell to as low as $79.40 a share Thursday. The stock is down 3.22% in the last month.

Emergent BioSolutions was expected to produce tens of millions of doses of the Johnson & Johnson vaccine in the coming months. The mishap will delay production and shipment schedules for weeks, according to the Times.

Johnson & Johnson fell as much as 1.3% Thursday before paring back losses.